Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Globe Newswire • 23 days ago
CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases...
Share to Feed
Duchenne is a genetic disorder, primarily affecting boys and is known to be fatal. This disease is claimed to affect roughly one in every 3,500 to 5,000 live
The post Solid Biosciences' SGT-003...
This indicator may be signaling that SLDB's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
This is a Bearish indicator signaling SLDB's price could decline from here. Traders may explore shorting the stock or put options...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
SGT-003 Granted Rare Pediatric Disease, Orphan Drug and Fast Track Designations in U.S. Site initiations scheduled for April; patient dosing expected to begin in Q2 2024 CHARLESTOWN, Mass...
Solid Biosciences (NASDAQ:SLDB - Get Free Report)s stock had its "outperform" rating reissued by stock analysts at William Blair in a research note issued on Thursday, MarketBeat reports. A...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
William Blair starts Solid Biosciences at outperform...
CHARLESTOWN, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases...